PALI earnings: next report 2026-08-10, real EPS beat/miss history, analyst consensus Buy, P/E -1.79. Updated 2026-07-23.
Palisade Bio (PALI) Research Hub
Palisade Bio (PALI) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 2.06 USD (+0.49%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -1.79, market cap 0.34B. This hub links to the full technical, earnings and options research available for PALI.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 2.06 USD (+0.49%) |
| 52-week range | 1.68 USD – 2.29 USD |
| Trend regime | Range |
| 14-day RSI | 46.8 (Neutral) |
| Trailing P/E | -1.79 |
| Market cap | 0.34B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-10 |
Available research for PALI
Covered Call on PALI: how it works, illustrative setup around the real 2.06 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on PALI: how it works, illustrative setup around the real 2.06 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on PALI: how it works, illustrative setup around the real 2.06 USD price, max profit/loss, breakeven and when to use it. Educational.
PALI technical analysis: range, last 2.06 USD, RSI 46.8, 52w range 1.68 USD–2.29 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is PALI in?
Palisade Bio (PALI) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is PALI in an uptrend or downtrend?
As of 2026-09-11, PALI is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is PALI's trailing P/E ratio?
PALI's trailing P/E is -1.79, with a market cap of 0.34B. See the earnings research page for full valuation detail.
When does PALI next report earnings?
PALI is next scheduled to report earnings on 2026-08-10, with a consensus EPS estimate of -0.05 USD.